AU2004267955A1 - Combination therapy for glycaemic control - Google Patents

Combination therapy for glycaemic control Download PDF

Info

Publication number
AU2004267955A1
AU2004267955A1 AU2004267955A AU2004267955A AU2004267955A1 AU 2004267955 A1 AU2004267955 A1 AU 2004267955A1 AU 2004267955 A AU2004267955 A AU 2004267955A AU 2004267955 A AU2004267955 A AU 2004267955A AU 2004267955 A1 AU2004267955 A1 AU 2004267955A1
Authority
AU
Australia
Prior art keywords
glutaminyl
pharmaceutically acceptable
thiazolidine
diabetes mellitus
pyrrolidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004267955A
Other languages
English (en)
Inventor
Hans-Ulrich Demuth
Konrad Glund
Matthias Hoffmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prosidion Ltd
Original Assignee
Prosidion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prosidion Ltd filed Critical Prosidion Ltd
Publication of AU2004267955A1 publication Critical patent/AU2004267955A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
AU2004267955A 2003-09-02 2004-09-02 Combination therapy for glycaemic control Abandoned AU2004267955A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49953503P 2003-09-02 2003-09-02
US60/499,535 2003-09-02
PCT/IB2004/003082 WO2005020983A2 (en) 2003-09-02 2004-09-02 Combination therapy for glycaemic control

Publications (1)

Publication Number Publication Date
AU2004267955A1 true AU2004267955A1 (en) 2005-03-10

Family

ID=34272835

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004267955A Abandoned AU2004267955A1 (en) 2003-09-02 2004-09-02 Combination therapy for glycaemic control

Country Status (14)

Country Link
US (1) US20060287251A1 (https=)
EP (1) EP1663200A2 (https=)
JP (1) JP2007504213A (https=)
KR (1) KR20060119927A (https=)
CN (1) CN1845731A (https=)
AU (1) AU2004267955A1 (https=)
BR (1) BRPI0413204A (https=)
CA (1) CA2536432A1 (https=)
EA (1) EA200600356A1 (https=)
IL (1) IL173844A0 (https=)
MX (1) MXPA06002127A (https=)
NO (1) NO20061085L (https=)
WO (1) WO2005020983A2 (https=)
ZA (1) ZA200601770B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0526291D0 (en) * 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
FR2896157B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
GB0623892D0 (en) * 2006-11-29 2007-01-10 Medical Res Council Technology Assay
EP2552952A1 (en) * 2010-03-26 2013-02-06 Novo Nordisk A/S Novel glucagon analogues
MX359329B (es) * 2011-10-28 2018-09-25 Sanofi Aventis Deutschland Una combinación farmacéutica para usarse en el tratamiento de un paciente que padece diabetes tipo 2.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19823831A1 (de) * 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE29924609U1 (de) * 1999-05-28 2004-04-22 Probiodrug Ag Neue Effektoren von Dipeptidylpeptidase IV
PT1741446E (pt) * 2000-01-21 2008-05-09 Novartis Pharma Ag Combinações incluindo inibidores da dipeptidilpeptidase-iv e agentes anti-diabéticos
US6890905B2 (en) * 2001-04-02 2005-05-10 Prosidion Limited Methods for improving islet signaling in diabetes mellitus and for its prevention
JP2005527504A (ja) * 2002-02-28 2005-09-15 プロシディオン・リミテッド グルタミニルを基礎するｄｐｉｖ阻害剤
WO2004031374A2 (en) * 2002-09-18 2004-04-15 Prosidion Ltd. Secondary binding site of dipeptidyl peptidase iv (dp iv)

Also Published As

Publication number Publication date
MXPA06002127A (es) 2006-05-31
EA200600356A1 (ru) 2006-08-25
EP1663200A2 (en) 2006-06-07
NO20061085L (no) 2006-05-31
CA2536432A1 (en) 2005-03-10
US20060287251A1 (en) 2006-12-21
JP2007504213A (ja) 2007-03-01
WO2005020983A3 (en) 2005-07-28
KR20060119927A (ko) 2006-11-24
IL173844A0 (en) 2006-07-05
ZA200601770B (en) 2007-07-25
WO2005020983A2 (en) 2005-03-10
CN1845731A (zh) 2006-10-11
BRPI0413204A (pt) 2006-10-03

Similar Documents

Publication Publication Date Title
US7078397B2 (en) Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
US7241756B2 (en) Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
ES2390231T3 (es) Agentes farmacéuticos concomitantes y su uso
US7935723B2 (en) Use of organic compounds
CA2622579C (en) Use of a dpp-iv inhibitor to reduce hypoglycemic events
Doupis et al. DPP4 inhibitors: a new approach in diabetes treatment
Ahrén et al. The islet enhancer vildagliptin: mechanisms of improved glucose metabolism
US20050107309A1 (en) Use of dipeptidyl peptidase IV effectors for normalizing the blood glucose level in mammals
KR20090038908A (ko) 대사 장애의 조합 치료
US20050014732A1 (en) Combination of an aldosterone receptor antagonist and an anti-diabetic agent
JP2009137973A (ja) 哺乳動物の血糖値低下のためのジペプチジルペプチダーゼｉｖエフェクターの使用
HK1218871A1 (zh) 药物组合物
EP1981495A2 (en) Use of vildagliptin for the treatment of diabetes
US20060287251A1 (en) Combination therapy for glycaemic control
SK287823B6 (sk) Pharmaceutical composition comprising 2 to 8 mg of 5-[4-[2-(N-2- methyl-N-pyridyl)amino)ethoxy]benzyl]tiazolidin-2,4-dione and sub-maximal amount of glimepiride and use thereof
Zito et al. Oral hypoglycemics: a review of chemicals used to treat type 2 diabetes
Dhanwal et al. DPP 4 Inhibitors-New paradigms in managing diabetes mellitus; A review
HK1165292A (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period